


FEWER TRIALS. MORE DISCOVERIES.

The Presentation is intended for educational and informational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the participants individually. The information is not designed to provide financial, tax planning, accounting, investment, business, or legal advice, in any way whatsoever. The reader should consult with a lawyer, accountant, and other professionals in respect of contents hereof. Furthermore, the information in no way should be construed or interpreted as, or as a part of, an offering or solicitation of securities. Investors are advised to discuss any trading with a registered securities broker or personal finance professional prior to investing.

This Presentation includes and is based on forward-looking information and statements that are subject to risks and uncertainties that could cause actual results to differ. Factors that might cause or contribute to such differences include, but are not limited to, economic conditions globally, the impact of competition, political and economic developments in the countries and states in which the Company operates, regulatory developments domestically and internationally. These expectations, estimates and projections are generally identifiable by statements containing words such as "expects", "anticipates", "targets", "goals", "projects", "intends", "plans", "believes", "seeks", "estimates", variations of such words, and similar expressions. Important factors that could cause actual results to differ materially from those expectations include, among others, economic and market conditions in the geographic areas and industries that are or will be major markets for the Company's businesses, market acceptance of new products and services, changes in governmental regulations, interest rates, fluctuations in currency exchange rates and such other factors as may be discussed from time to time. Although the Company believes that its expectations and the information in this Presentation were based upon reasonable assumptions at the time when they were made, it can give no assurance that those expectations will be achieved or that the actual results will be as set out in this Presentation. The Company is not making any representation or warranty, expressed or implied, as to the accuracy, reliability, or completeness of the information in the Presentation, and neither the Company nor any of its directors, officers, or employees will have any liability to the reader or any other persons resulting from the reader's use of the information in the Presentation. The Company undertakes no obligation to publicly update or revise any forward-looking information or statements in the Presentation. The reader should consult any further disclosures the Company may make in documents it files with the applicable securities regulators.



FEWER TRIALS. MORE DISCOVERIES.




OUR COMPANY



Telescope Innovations Corp. is a technology company that leverages a unique combination of automation, analytics, and chemical process manufacturing expertise to develop next-generation technology platforms.


We deploy these platforms through partnerships to resolve bottlenecks and inefficiencies in chemical and pharmaceutical manufacturing.



WHAT WE DO



Our core platform technology breaks down barriers in process chemistry to yield greater efficiency, higher productivity, and more impactful discoveries.



WHO WE ARE



Our award-winning scientific leadership has collectively authored over 450 academic publications and 34 patents.



PROF. JASON HEIN
CEO

Leads one of the largest academic chemistry research groups in Canada. Has authored 50+ peer-reviewed articles amassing over 4,000 citations.



PROF. BARRY SHARPLESS
SENIOR ADVISOR

Received the Nobel Prize in Chemistry in 2001 for “the most important discovery in the field of synthesis during the past few decades”.



PALOMA PRIETO
VP, OPERATIONS

Stewards multimillion-dollar research programs in pharmaceutical chemistry, process manufacturing, and automated, self-driving laboratories.



SHAD GRUNERT
VP, INNOVATION

16 years of experience in deploying and designing chemistry laboratory technology, with an emphasis on integrated and collaborative automation.



DR. LARS YUNKER
VP, AUTOMATION

Integrates automation for robotic and analytical chemistry systems, including Project Ada, the world’s first self-driving laboratory for thin film material discovery.

WHO WE ARE



Our directors bring over 60 years combined experience in building technology companies and successfully managing companies in the capital markets.



DR. ANDY ROBINSON

An experienced scientist with a 20+ year successful track record in creating concepts, building companies and teams, and then taking them to successful execution. Andy has held executive and board positions with a range of public and private companies. He is the President, COO & Director of Standard Lithium, a company leveraging unique process chemistry to build the first American commercial lithium project in over 50 years.



ROBERT MINTAK

20+ years experience in corporate management in a wide range of private and public companies with a specific emphasis on strategic development, corporate governance and long-term creation of shareholder value. As the CEO of Standard Lithium, he has led the company to its position among the 50 best performers on the OTCQX market.



ALI PEJMAN

20+ years experience as an Investment Banker having advised over \$25 Billion in M&A transactions and \$3Billion in equity financings. He is currently Managing Partner at Fort Capital, a boutique investment bank. Pejman is an active angel investor and Associate of the Creative Destruction Labs, with current and prior Board positions on Science World, Vancouver Transit Police, and Vancouver/UBC General Hospital. He has been instrumental in large purposed fundraising for brain research and care.



PROF. JASON HEIN

At the University of British Columbia, Prof. Hein heads one of the largest academic chemistry research groups in Canada. He has authored over 50 peer-reviewed articles amassing over 4,000 citations on crystallization, purity, commercial scale-up and the role of automation, robotics and AI in controlling pharmaceutical production.



HENRY DUBINA

As the President and Head of Mettler-Toledo AutoChem for over 20 years, he directed the global business from Research & Development, Manufacturing, and Marketing, to Sales and Service. AutoChem instruments have been ubiquitously deployed in academia and industry for biopharmaceutical, chemical, and advanced materials applications to boost R&D productivity.

STRATEGIC PARTNERS AND CLIENTS



SCIENTIFIC
INSTRUMENTATION
COMPANIES




PHARMACEUTICAL
COMPANIES




MINING
COMPANIES



CONSULTING
ENGINEERING
COMPANIES






TELESCOPE AUTOMATION



TELESCOPE AUTOMATION



We combine robotic automation, online analysis, and machine learning to guide chemistry decision-making.



Adaptive automation



Quality controls



Higher quality data
and measurements



Fewer experiments
required



Fewer trials,
more discoveries

CURRENT FOCUS:



Fully automated workflows
and self-driving labs





Innovative systems for direct
chemical analysis



TELESCOPE AUTOMATION

Traditional R&D is the “blind” search for new processes and chemicals. Finding specific chemical pathways requires labour-intensive trial and error.

Telescope Automation transforms this approach with more efficient tools and techniques.



TELESCOPE AUTOMATION: DILC PRODUCT LINE



A game-changing tool to visualize and understand chemical reactions



Already deployed by five major global pharmaceutical companies



Rapid, real-time sampling frequency



Comprehensive reaction profiling




Compatible with heterogeneous, air- and water-sensitive reactions

DILC

DIRECT INJECT
LIQUID CHROMATOGRAPHY



TELESCOPE AUTOMATION: ACCOMPLISHMENTS AND PATHS TO COMMERCIALIZATION





**TELESCOPE
INDUSTRIES**





TELESCOPE INDUSTRIES

We apply our technology to enable faster, more reliable process scale up. Our current focus is process innovation for the battery materials.

Conventional stepwise chemical plants are:




Slow to scale



Costly to build



Generate large amounts of waste



CURRENT FOCUS:



Material refinement for batteries



Carbon capture and utilization


TELESCOPE INDUSTRIES: COMMON INEFFICIENCIES IN CHEMICAL MANUFACTURING



Complicated supply chains



High equipment CapEx



Low process efficiency of
stepwise batch production

Large volumes of waste generated



TELESCOPE INDUSTRIES:



We utilize our tools to develop and scale chemical manufacturing processes.

OUR TOOLS



ROBOTICS AND
AUTOMATION




ONLINE
ANALYSIS

THE RESULTS



FASTER SCALE UP



FEWER PROCESS
STEPS

CURRENT FOCUS:



Material refinement for batteries




Carbon capture and utilization

PROJECT HIGHLIGHT: LITHIUM REFINEMENT




We are optimizing lithium refinement technology in partnership with **Standard Lithium** . Our improvements enable higher extraction efficiency of low-grade brines.

We are also exploring the utilization and sequestration of CO₂ within SLI's process.



TELESCOPE INDUSTRIES: ACCOMPLISHMENTS AND PATHS TO COMMERCIALIZATION





TELESCOPE
INNOVATION



**TELESCOPE
HEALTH**



TELESCOPE HEALTH

Telescope provides enabling technology and manufacturing processes for the pharmaceutical industry. We uncover and develop efficient routes to manufacturing new medicines.



CURRENT FOCUS:



Novel access to emerging psychedelic markets (Psilocybin)




Process optimization for critical therapeutic targets.

TELESCOPE HEALTH




Barriers to the large-scale deployment of novel therapeutic compounds:



Laborious and time consuming manufacturing processes



Unsafe reaction routes



Complex reaction conditions



Variability in reproducibility




TELESCOPE HEALTH

Our core technology accelerates research and paves the way for accessing novel therapeutics.



NOVEL, NEXT GENERATION COMPOUNDS

TELESCOPE HEALTH: ACCOMPLISHMENTS AND PATHS TO IP COMMERCIALIZATION





BUSINESS CASE & SHAREHOLDER VALUE PROPOSITION



STRATEGIC PARTNERS AND CLIENTS



SCIENTIFIC
INSTRUMENTATION
COMPANIES




PHARMACEUTICAL
COMPANIES



MINING
COMPANIES




CONSULTING
ENGINEERING
COMPANIES




COMPARABLES



-  AUTOMATION
-  INDUSTRIES
-  HEALTH



BUSINESS MODEL



STRATEGIC MILESTONES



ACCOMPLISHED

NEXT 12 MONTHS

AUTOMATION

- Launched DILC product, onboarding units in several pharmaceutical companies
- Completed proof-of-concept work for fully automated lab workflows with a major global pharmaceutical company

- Position DILC as industry standard technology for pharmaceutical R&D
- Establish Telescope as a partner-of-choice for laboratory automation integration

INDUSTRIES

- Engaged in >\$1M contract research agreements with mining companies

- Leverage and develop new IP to address industry manufacturing pain points

HEALTH

- Submitted PCT on novel manufacturing methods for psilocybin and related compounds

- Monetize IP portfolio through partnerships with manufacturers and developers of mental health therapeutics

CAPITALIZATION



Telescope Innovations Corp. Capital Structure May 10, 2022	Price (Ave)	Number
Shares issued		48,786,070
Stock options	\$1.49	3,425,000
Warrants	\$ —	—
Fully Diluted Share Position		52,211,070

Shares held by Directors/Officers – 10,143,741 | 21%



THANK YOU

Contact: info@telescopeinn.com

FEWER TRIALS. MORE DISCOVERIES.